background
spread
novel
coronaviru
previous
name
alreadi
taken
pandem
proport
affect
countri
matter
week
elucid
diagnost
valu
differ
method
especi
auxiliari
diagnosi
valu
antibodi
assay
infect
help
improv
sensit
pathogenicdiagnosi
provid
time
treatment
differenti
infect
case
healthi
thu
prevent
epidem
method
medic
record
patient
confirm
infect
second
peopl
hospit
fuyang
januari
februari
collect
retrospect
analyz
specimen
includ
throat
swab
sputum
serum
collect
hospit
period
viral
rna
serum
igmigg
antibodi
measur
respect
detect
differ
method
well
auxiliari
diagnosi
valu
antibodi
test
infect
analyz
result
among
patient
total
seroposit
rate
igm
igg
respect
two
patient
remain
seroneg
throughout
cours
ill
earli
phase
ill
rna
test
sputum
specimen
possess
highest
detect
follow
rna
test
throat
swab
antibodi
assay
present
lower
posit
rate
igm
igg
sensit
antibodi
assay
overtook
rna
test
sinc
day
onset
igm
igg
note
posit
rate
throat
swab
case
later
phase
dao
sensit
igm
igg
rose
respect
combin
use
antibodi
assay
qrtpcr
time
abl
improv
sensit
pathogenicdiagnosi
especi
throat
swab
group
later
stage
ill
moreov
case
undetect
viral
rna
throat
swab
specimen
earli
stage
ill
abl
igmigg
seroposit
day
antibodi
detect
offer
vital
clinic
inform
physician
could
use
effect
supplementari
indic
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
outbreak
coronaviru
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
infect
continu
spread
worldwid
becom
global
threat
march
reach
countri
case
death
world
health
organ
declar
outbreak
pandem
rate
global
risk
assess
higha
global
respons
prepar
health
system
worldwid
imper
time
accur
diagnosi
suspect
infect
isol
care
patient
earli
great
import
interrupt
humantohuman
transmiss
limit
spread
viru
common
laboratori
abnorm
confirm
case
includ
decreas
white
blood
cell
lymphocyt
platelet
count
increas
ldh
ck
crp
level
report
common
clinic
symptom
includ
fever
cough
myalgia
fatigu
howev
abnorm
symptom
uniqu
featur
sinc
might
similar
viru
infect
diseas
meanwhil
infect
patient
asymptomat
also
becom
sourc
infect
make
earli
diagnosi
essenti
use
quantit
realtim
pcr
qrtpcr
assay
detect
viral
nucleic
acid
becom
primari
crucial
diagnost
approach
identif
infect
still
limit
clinic
practic
rnabas
diagnost
test
give
posit
result
viru
still
present
test
could
identifi
peopl
infect
past
recov
clear
viru
bodi
addit
neglig
falseneg
risk
brought
pcr
test
report
posit
rate
vari
differ
specimen
patient
number
case
epidemiolog
link
exposur
typic
lung
ct
imag
still
remain
rna
neg
respiratori
tract
specimen
iggigm
antibodi
test
serolog
test
method
ad
diagnost
criteria
china
updat
version
diagnosi
treatment
guidelin
march
help
trace
much
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
populationbas
way
whether
person
infect
past
sinc
bodi
could
retain
antibodi
viru
alreadi
overcomewhil
assay
still
need
care
valid
sure
could
react
antibodi
similar
virus
might
lead
crossreact
also
still
fals
posit
fals
neg
result
iggigm
antibodi
test
herein
urgent
need
elucid
diagnost
accuraci
differ
specimen
method
improv
posit
rate
prevent
viru
transmiss
assur
time
treatment
patient
respiratori
specimen
includ
throat
swab
sputum
collect
throat
swab
place
steril
test
tube
ml
steril
salin
sputum
sampl
ad
equal
volum
acetylcystein
shaken
room
temperatur
min
fulli
liquefi
next
total
rna
extract
use
viral
nucleic
acid
isol
kit
jiangsu
bioperfectu
technolog
compani
ltd
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
serum
igg
igm
antibodi
test
use
gica
kit
accord
manufactur
protocol
innovita
biolog
technolog
co
ltd
briefli
test
serum
sampl
sampl
diluent
ad
onto
pad
test
strip
strip
place
flat
room
temperatur
react
result
could
judg
accord
color
test
control
line
detect
band
control
band
turn
red
sampl
interpret
control
band
turn
red
detect
band
interpret
neg
neither
band
color
test
reagent
assum
work
requir
confirm
retest
analys
perform
use
spss
continu
variabl
data
median
interquartil
rang
iqr
categor
variabl
express
frequenc
percentag
chisquar
test
yate
correct
fisher
exact
test
use
comparison
group
p
consid
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
statist
signific
medic
record
patient
collect
retrospect
analyz
median
age
year
iqr
male
patient
case
sever
critic
condit
rest
mild
case
median
number
specimen
collect
patient
analyz
detect
rna
test
antibodi
assay
accord
time
cours
sinc
ill
onset
cohort
result
shown
tabl
earli
phase
ill
within
sinc
onset
rna
test
sputum
specimen
possess
highest
detect
follow
rna
test
throat
swab
antibodi
assay
present
lower
posit
rate
igm
igg
sensit
antibodi
assay
overtook
rna
test
sinc
day
onset
igm
igg
note
posit
rate
throat
swab
case
later
phase
dao
sensit
igm
igg
rose
respect
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
base
mention
find
aim
evalu
auxiliari
diagnosi
valu
antibodi
assay
suspect
case
neg
nucleic
acid
detect
firstli
detect
antibodi
assay
patient
undetect
viral
rna
respiratori
tract
specimen
analyz
result
shown
tabl
tabl
combin
use
test
rna
antibodi
assay
time
abl
improv
sensit
pathogenicdiagnosi
infect
especi
throat
swab
group
later
stage
illnessthen
analyz
antibodi
test
data
case
undetect
viral
rna
throat
swab
specimen
earli
stage
ill
shown
igmigg
seroposit
day
neg
nucleic
acid
test
result
igm
igg
suggest
auxiliari
diagnosi
valu
antibodi
assay
spread
novel
coronaviru
recent
identifi
patient
acut
respiratori
diseaseit
third
highli
pathogen
transmiss
coronaviru
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
emerg
human
effect
diagnosi
identifi
infect
peopl
great
import
public
health
effort
individu
health
concern
patient
clinic
manifest
mainli
includ
fever
cough
dyspnea
myalgia
fatigu
radiograph
evid
pneumonia
diagnosi
could
base
clinic
histori
laboratori
ct
imag
confirm
primarili
reli
nucleic
acid
detect
yet
mani
novel
coronaviru
pneumonia
patient
diagnos
due
neg
nucleic
acid
test
exampl
throat
swab
commonli
use
nucleic
acid
test
viral
load
upper
respiratori
tract
sampl
usual
much
lower
lower
respiratori
tract
sampl
case
viral
load
patient
vari
differ
stage
ill
consequ
problem
lead
urgent
need
clinic
auxiliari
diagnosi
improv
posit
detect
rate
provid
time
treatment
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
prevent
quarantin
human
immun
system
produc
specif
igm
igg
antibodi
viru
infect
igm
earliest
antibodi
appear
upon
first
immun
respons
serolog
presenc
igm
indic
recent
infect
could
use
auxiliari
diagonosi
earli
infect
igg
produc
later
last
long
use
indic
previou
secondari
infect
studi
posit
rate
throat
swab
case
later
phase
dao
sensit
igm
igg
respect
combin
use
antibodi
assay
time
could
abl
greatli
improv
sensit
pathogenicdiagnosi
infect
especi
throat
swab
group
later
stage
illnessmoreov
analysi
antibodi
test
data
case
undetect
viral
rna
throat
swab
specimen
earli
stage
ill
suggest
case
could
igmigg
seroposit
day
neg
nucleic
acid
test
result
indic
auxiliari
diagnosi
valu
antibodi
assay
note
still
fals
posit
fals
neg
result
antibodi
assay
igm
igg
level
detect
limit
test
result
would
neg
furthermor
igm
antibodi
would
gradual
decreas
disappear
week
igm
level
might
peak
detect
casesmeanwhil
differ
individu
immun
respons
might
result
fals
neg
result
suspect
case
patient
produc
antibodi
produc
antibodi
rel
late
might
relaps
immun
reduc
conclus
test
igm
igg
antibodi
provid
import
immunolog
evid
physician
could
use
effect
supplementari
indic
suspect
case
neg
viral
nucleic
acid
detect
conjunct
nucleic
acid
detect
diagnosi
suspect
case
combin
nucleic
acid
rtpcr
igmigg
antibodi
test
provid
accur
infect
diagnosismor
research
develop
iggigm
combin
antibodi
test
kit
need
encourag
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
